title: The recipient CXCL10 + 1642C>G variation predicts survival outcomes after HLA fully matched unrelated bone marrow transplantation.
abstract: CXCL10 is a chemoattractant for immune cells that is involved in several immune-inflammatory disorders. This study retrospectively examined the impact of a single nucleotide variation (rs3921, +1642C>G) in the CXCL10 gene on transplant outcomes in a cohort of 652 patients who underwent unrelated HLA-matched bone marrow transplantation (BMT) for hematologic malignancies. The recipient C/G or G/G genotype was found to be associated with a significantly better 5-year overall survival (OS) rate and a lower transplant-related mortality (TRM) rate than the recipient C/C genotype. The recipient C/G or G/G genotype also predicted a reduced incidence of death due to organ failure. The multivariate analysis showed the recipient C/G or G/G genotype to exhibit statistical trends toward beneficial effects on OS but not on TRM. CXCL10 genotyping could therefore be useful in predicting prognoses and creating therapeutic strategies for improving the final outcomes of patients who undergo allogeneic BMT.
authors.affiliation: Department of Hematology and Oncology, Kanazawa University Hospital, Kanazawa, Japan. bn6a-tkm@asahi-net.or.jp
authors.forename: Katsuya
authors.initials: K
authors.lastname: Nakata
authors.forename: Akiyoshi
authors.initials: A
authors.lastname: Takami
authors.forename: J Luis
authors.initials: JL
authors.lastname: Espinoza
authors.forename: Keitaro
authors.initials: K
authors.lastname: Matsuo
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Morishima
authors.forename: Makoto
authors.initials: M
authors.lastname: Onizuka
authors.forename: Takahiro
authors.initials: T
authors.lastname: Fukuda
authors.forename: Yoshihisa
authors.initials: Y
authors.lastname: Kodera
authors.forename: Hideki
authors.initials: H
authors.lastname: Akiyama
authors.forename: Koichi
authors.initials: K
authors.lastname: Miyamura
authors.forename: Takehiko
authors.initials: T
authors.lastname: Mori
authors.forename: Shinji
authors.initials: S
authors.lastname: Nakao
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000276:immunology* / Q000401:mortality; D054357:Chemokine CXCL10 / Q000008:administration & dosage / Q000235:genetics* / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005838:Genotype; D006680:HLA Antigens / Q000008:administration & dosage / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000235:genetics / Q000276:immunology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000276:immunology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000276:immunology / Q000628:therapy; D012189:Retrospective Studies; D016019:Survival Analysis; D061349:Unrelated Donors
chemical_list: C114753:CXCL10 protein, human; D054357:Chemokine CXCL10; D006680:HLA Antigens